Valeant Ends Fight With Par Over Generic Antidepressant

Law360, San Diego (December 9, 2011, 10:16 PM EST) -- A unit of Valeant Pharmaceuticals International Inc. on Thursday resolved its suit in New York federal court accusing Par Pharmaceutical Cos. Inc. of infringing its patents by seeking to launch a generic version of Valeant’s antidepressant Aplenzin.

U.S. District Judge Richard Berman signed off on the parties’ bid to dismiss their claims against each other with prejudice after Par stipulated that the proposed generic drug would infringe Valeant International (Barbados) SRL’s patents-in-suit.

The parties agreed to cover their own attorneys’ fees and costs. Attorneys representing Valeant...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.